ICU Medical Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $548 million, a 6% increase on an organic basis (1% reported), impacted by the deconsolidation of IV Solutions.

Adjusted Gross Margin: 41%.

Adjusted EBITDA: $110 million, representing a 20% margin and a 10% year-over-year growth.

Adjusted EPS: $2.37, up 13% from $2.10 in Q2 2025.

Free Cash Flow: $62 million, including $20 million from tariff refunds.

Debt Repayment: $50 million in the quarter, reducing net leverage to 2.3x.

Updated Guidance: Adjusted EBITDA guidance raised to $415-$435 million; adjusted EPS guidance raised to $8.60-$9.00.

2Strategic Updates and Business Highlights

Consumables Business: Grew 6% reported and 5% organic, achieving record sales across all product families.

IV Systems Business: Grew 13% reported and 12% organic, with strong performance in pumps and dedicated sets, despite ongoing declines in OEM revenues.

Vital Care: Experienced a 4% organic decline and a 32% reported decline due to the deconsolidation of IV Solutions, but showed sequential improvement.

Innovation Focus: Continued investment in R&D and new product cycles, including progress on the Medfusion 5000 syringe pump and new infusion devices.

Joint Venture Update: Otsuka announced a $0.5 billion investment in IV Solutions production, enhancing ICU Medical's market position.

3Forward Guidance and Outlook

Growth Expectations: Anticipate continued organic growth at or above 6% for the remainder of the year.

Margin Expansion: Targeting an adjusted gross margin of approximately 41.5% for the full year, driven by lower tariffs and operational synergies.

Free Cash Flow Target: Aiming for $150 million for the year, with expectations of reduced restructuring and remediation spending in the second half.

4Bad News, Challenges, or Points of Concern

Currency Headwinds: Negative impacts from the Costa Rican Colon, Mexican Peso, and Japanese Yen, cumulatively affecting earnings by approximately $60 million over four years.

Tariff Costs: Ongoing tariffs are expected to cost $30-$40 million annually, impacting profitability.

Vital Care Stability: While stabilizing, the business remains under pressure, and management is cautious about pursuing any value-destructive deals.

5Notable Q&A Insights

Infusion Systems Growth: The 12% growth was attributed to competitive wins and early installations, with no significant uptick in replacement cycles yet.

Pricing Dynamics: Pricing for new products like Duo and Solo is holding steady, aligned with their perceived value.

Future Installations: Management expects continued strong performance in Infusion Systems, with growth driven by competitive wins rather than a broad market acceleration.

Tariff Refunds: Potential for additional refunds exists, but the timing and amounts remain uncertain.

Operational Efficiencies: Improvements in IT systems contributed to lower SG&A expenses, but the current run rate may not be sustainable without further investment. Overall, ICU Medical reported solid financial results and maintained a positive outlook, while also acknowledging ongoing challenges related to tariffs, currency fluctuations, and the performance of the Vital Care segment.